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Pulmonary neuroendocrine cells are typically found either singly or in small clusters,termed neuroepithelial bodies, in the basilar region of the distal bronchiolar epithe-
lium. Neuroendocrine cells contain multiple biologically active neuropeptides and could
potentially contribute to diverse physiologic responses, including fibrosis, bronchocon-
striction, and cough. In the normal adult lung, neuroendocrine cells are rare. Increased
numbers of neuroendocrine cells are found in fetal lung as well as in association with lung
injury, including bronchopulmonary dysplasia, cystic fibrosis, and other forms of bron-
chiectasis. In animal models of airway injury, regeneration of the airway epithelium
originates in Clara cell secretory protein expressing cells adjacent to or within neuroep-
ithelial bodies, suggesting a role of the neuroepithelial body in either providing or
nurturing multipotent airway epithelial progenitor cells.
A rare syndrome of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
(DIPNECH), characterized by florid hyperplasia of neuroendocrine cells in the distal
airways with obstructive bronchiolitis, was described in 1992.1 The clinical manifestations
of DIPNECH are most typically a chronic cough and dyspnea with an indolent, slowly
progressive course; carcinoid tumors are also frequent.2 The pathologic features of
DIPNECH can often be found in carcinoid resection specimens, although the full-blown
clinical syndrome is less common.3,4 The disorder is typically not suspected before lung
biopsy but can be presumptively diagnosed in the setting of a compatible clinical history
with a high-resolution computed tomography scan revealing air trapping demonstrated by
mosaic attenuation, sometimes accompanied by multiple small nodules and airway wall
thickening.5 For unknown reasons, DIPNECH is predominantly found in middle-aged
women. Treatment is largely unsuccessful, although there are cases with improvement in
cough (and less frequently in pulmonary function testing) after octreotide. No other
treatment is known to be effective for DIPNECH.
In this issue of Journal of Thoracic Oncology, Irshad et al.6 describe an unique case
of DIPNECH with unilateral involvement radiographically and on transbronchial lung
biopsy. These features suggest limited local spread throughout the airways. The patient
was treated with pneumonectomy and to date has not recurred on the uninvolved side. The
presentation and clinical decision making of this case are fascinating, but can we learn
something about DIPNECH from this experiment of nature?
DIPNECH seems to share some features with another orphan disease that affects
females, lymphangioleiomyomatosis (LAM). LAM is characterized by progressive cystic
lung disease accompanied by proliferation and lymphatic spread of cells with a smooth
muscle phenotype, termed LAM cells, renal angiomyolipomas, and uterine myomas.7
Research in LAM has been fostered by an active advocacy group, the LAM Foundation,
and a key clue to the molecular pathogenesis was provided by the finding of LAM, similar
to sporadic cases, in patients with tuberous sclerosis. Investigators found that LAM cells
in sporadic LAM harbor mutations in the tuberous sclerosis genes, TSC1 and TSC2,
whereas other cells are spared this mutation. Thus, sporadic LAM results from a somatic
mutation resulting in a clonal population of cells that proliferate and spread through a
mechanism of limited metastasis via lymphatics. Analysis of the pathways inhibited by the
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TSC genes has led to the rational design of a clinical trial
utilizing an mTOR inhibitor with some success.8
This phenomenon of expansion and limited dissemina-
tion of a clonal population of cells with a somatic mutation
has been documented to also occur within the respiratory
epithelium. A patient without lung cancer, but who had
multiple premalignant dysplastic lesions, was shown to har-
bor a subpopulation of epithelial cells with a dominant
negative p53 mutation dispersed throughout the airways of
both lungs in 1997.9 More recently, the mutational analysis of
airway epithelium distant from adenocarcinomas in resection
specimens has demonstrated that common activating epider-
mal growth factor receptor mutations can frequently be found
both in malignant and nonmalignant tissue.10
It is tantalizing that several cases of DIPNECH have
been reported in patients with features of multiple endocrine
neoplasia type I (MEN1).2,11 The MEN1 gene frequently
exhibits loss of function in carcinoid tumors and seems a
prime candidate for a somatic mutation affecting neuroendo-
crine cells in DIPNECH.12 I speculate that MEN1 or other
somatic mutations limited to hyperplastic neuroendocrine
cells will eventually be identified in DIPNECH. This infor-
mation should lead to the rational choice of targeted therapy
to treat this orphan disease.
REFERENCES
1. Aguayo SM, Miller YE, Waldron JA Jr, et al. Brief report: idiopathic
diffuse hyperplasia of pulmonary neuroendocrine cells and airways
disease. N Engl J Med 1992;327:1285–1288.
2. Davies SJ, Gosney JR, Hansell DM, et al. Diffuse idiopathic pulmonary
neuroendocrine cell hyperplasia: an under-recognised spectrum of dis-
ease. Thorax 2007;62:248–252.
3. Miller RR, Muller NL. Neuroendocrine cell hyperplasia and obliterative
bronchiolitis in patients with peripheral carcinoid tumors. Am J Surg
Pathol 1995;19:653–658.
4. Aubry MC, Thomas CF Jr, Jett JR, et al. Significance of multiple
carcinoid tumors and tumorlets in surgical lung specimens: analysis of
28 patients. Chest 2007;131:1635–1643.
5. Lee JS, Brown KK, Cool C, et al. Diffuse pulmonary neuroendocrine
cell hyperplasia: radiologic and clinical features. J Comput Assist
Tomogr 2002;26:180–184.
6. Irshad S, Mcclean E, Rankin S, et al. Unilateral diffuse idiopathic
pulmonary neuroendocrine cell hyperplasia (DIPNECH) and multiple
carcinoids treated with pneumonectomy. J Thorac Oncol 2010;5:921–
923.
7. Juvet SC, McCormack FX, Kwiatkowski DJ, et al. Molecular pathogen-
esis of lymphangioleiomyomatosis: lessons learned from orphans. Am J
Respir Cell Mol Biol 2007;36:398–408.
8. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyo-
lipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
N Engl J Med 2008;358:140–151.
9. Franklin WA, Gazdar AF, Haney J, et al. Widely dispersed p53 mutation
in respiratory epithelium. A novel mechanism for field carcinogenesis.
J Clin Invest 1997;100:2133–2137.
10. Tang X, Shigematsu H, Bekele BN, et al. EGFR tyrosine kinase domain
mutations are detected in histologically normal respiratory epithelium in
lung cancer patients. Cancer Res 2005;65:7568–7572.
11. Fessler MB, Cool CD, Miller YE, et al. Idiopathic diffuse hyperplasia
of pulmonary neuroendocrine cells in a patient with acromegaly.
Respirology 2004;9:274–277.
12. Debelenko LV, Brambilla E, Agarwal SK, et al. Identification of MEN1
gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet
1997;6:2285–2290.
Miller Journal of Thoracic Oncology • Volume 5, Number 6, June 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer762
